Rani Therapeutics (RANI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$4.9M

Revenue (quarter)

$1.7M

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

$4.9M

Gross margin

100.00%

Net income (trailing twelve months)

−$33.4M

Net income (quarter)

−$8.4M

Net income growth (year over year)

+24.97%

Net margin

−685.34%

Return on equity

−179.10%

EPS (trailing twelve months)

−$0.13

Book value per share

$0.29

P/E (trailing twelve months)

—

Price to book

1.98

Debt to assets

21.13%

Payout ratio

—

Dividend yield

—

Company profile

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

• Is Rani Therapeutics (RANI) profitable?

  No. Rani Therapeutics reported a net loss of $33.4M over the trailing twelve months.

• How much revenue does Rani Therapeutics (RANI) make?

  Rani Therapeutics generated $4.9M in revenue over the trailing twelve months.

• How do I buy stock in Rani Therapeutics (RANI)?

  RANI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.